UPS, FedEx and logistics giants are investing within the healthcare increase

As demand rises for specialised medicines like GLP-1s, logistics firms together with UPS and FedEx are adapting their methods to have the ability to higher ship and retailer these prescribed drugs.

Most injectable GLP-1 medicines, together with Novo Nordisk‘s Ozempic and Wegovy and Eli Lilly‘s Mounjaro and Zepbound, require refrigerated storage for cargo.

The Covid pandemic put healthcare logistics at heart stage in 2020, because the delivery of temperature-controlled vaccines shortly turned a vital a part of preserving the virus at bay. And as extra money has been poured into new pharmaceutical improvements, the transportation of these merchandise have come underneath the highlight.

Logistics firms are actually investing hundreds of thousands of {dollars} and strengthening dozens of temperature-controlled services to faucet into the market.

In June, UPS introduced a brand new $48 million funding in temperature-controlled services because it sees a rising demand for important remedies. Based on Development Market Reviews, the demand for temperature-sensitive biologics is projected to develop at an 8.3% compound annual progress price by means of 2033 and attain a market worth of roughly $39.1 billion.

Weight problems and diabetes medication, in the meantime, have been booming in reputation. A July Gallup ballot discovered that 11% of Individuals take GLP-1 medicines for weight reduction functions in 2026, up from simply 3% in 2024.

But when they are not saved and shipped on the appropriate temperature, they danger shedding their efficacy.

The Meals and Drug Administration has warned that improper storage throughout delivery can have an effect on the medication’s high quality and recommends sufferers don’t use GLP-1 medication that arrive “heat or with inadequate refrigeration.”

Different biologics, like some vaccines, insulin and antibiotics, additionally require specialised cargo to keep up efficacy. For logistics firms, which means guaranteeing the right storage and motion each step of the best way.

“One of many greatest alternatives we see is supporting the shift towards extra specialised therapies and extra care delivered outdoors of conventional healthcare settings,” Bolla mentioned.

He mentioned UPS is experiencing “speedy progress” in biologics, cell and gene therapies, although the most important problem is that the margin for error is small — even a short stray from the proper temperature can break the medicines, Bolla mentioned.

“However that is additionally what’s creating such a big alternative in healthcare logistics,” he mentioned. “As remedies grow to be extra specialised and provide chains grow to be extra complicated, healthcare firms want companions that may present not simply temperature-controlled storage or transportation, however end-to-end visibility, management and reliability throughout the complete community.”

FedEx can be tapping into the development, launching a life sciences group earlier this month particularly to assist the motion of prescribed drugs and different healthcare merchandise.

On an earnings name in June, FedEx’s Chief Buyer Officer Brie Carere advised analysts that healthcare transportation income in fiscal yr 2026 reached practically $10 billion.

“We’re constructing end-to-end options centered on world pharma clients, and what’s so necessary with world pharma is that you need to acknowledge that there is a affected person on the finish of each supply or somebody that is ready to be handled,” mentioned Nick Gennari, FedEx’s president of healthcare. “So we take this very, very severely.”

With GLP-1s particularly, Gennari mentioned there’s an growing complexity to delivering these medicines, with kinds starting from injectables to oral capsules and going direct-to-consumer. However with that complexity comes a progress alternative for FedEx, which he mentioned is “ideally positioned.”

Gennari mentioned FedEx has specialised know-how, together with its machine studying engine that enables clients to see product motion with predictive talents, in addition to its know-how that identifies healthcare merchandise and treats every in a different way relying on its distinctive wants.

Gennari additionally mentioned he is “very comfy” with the corporate’s base capabilities and its plans for enlargement, together with cold-chain logistics.

“A lot of the infrastructure that is required to achieve success on this house, we have already got. Now we have the airline; we now have an unbelievable schedule; we now have the elevate capabilities. The community is hardened and works very nicely,” he mentioned.

C.H. Robinson advised CNBC the logistics firm had surpassed $1 billion in income in healthcare logistics alone over the previous yr, largely as a result of progress in GLP-1 medication, because it has been investing in temperature-controlled services.

“It’s good to actually have that end-to-end connectivity, so you have to have a very nice community and infrastructure constructed out with a purpose to correctly service the healthcare clients,” mentioned Ronnie Davis, the corporate’s vice chairman of North American floor transportation.

Davis mentioned the availability chain for medicines has additionally grow to be extra sophisticated. Along with requiring refrigeration, many medication have a brief shelf life and must be delivered in exact home windows of time.

“A variety of the innovation has been on getting the medication to the market,” Davis mentioned. “I feel what you are beginning to see is that is actually placing stress on the capabilities of the chilly chain provide chains within the market. … With the rise of GLP-1s and different specialised drugs, it is actually making a aggressive nature for a similar refrigerated provide assets which might be there and, fairly candidly, that offer is just not limitless, it is constrained.”

Davis mentioned C.H. Robinson is working to amp up its capabilities, particularly to maintain up with the upper quantity. On the similar time, he added, pharma firms are additionally making an attempt to get inventive to deliver their merchandise to market with an extended shelf life.

That innovation can be intersecting with the expansion of synthetic intelligence capabilities, in line with Hendrik Venter, CEO of DHL Provide Chain. The logistics firm makes use of AI to observe important life science merchandise, monitoring temperatures and anticipating the place a difficulty may occur.

“You are seeing the business shifting from standard to biopharma,” Venter advised CNBC. “It’s good to have a provide chain that’s resilient and able to delivery in all of those numerous temperature zones.”

The corporate introduced final yr that it plans to speculate 2 billion euros ($2.25 billion) in well being logistics by 2030, with half of that allotted to the Americas.

A variety of pharmaceutical firms are additionally outsourcing their warehousing actions to DHL, Venter mentioned. The corporate takes over these services, manages them and integrates them into the remainder of their community.

DHL launched a pharmaceutical air hall all over the world, with a devoted plane and linked community that ensures the medication usually are not being shipped by means of separate regulatory environments.

“You can’t lose a cargo. You can’t exchange it. It must be delivered on time, each time, in the fitting high quality and temperatures,” Venter mentioned. “So we proceed to selectively take a look at how one can strengthen that community.”